United States v. Sanofi Aventis U.S. LLC

CourtSupreme Court of Delaware
DecidedMarch 17, 2020
Docket256, 2019
StatusPublished

This text of United States v. Sanofi Aventis U.S. LLC (United States v. Sanofi Aventis U.S. LLC) is published on Counsel Stack Legal Research, covering Supreme Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Sanofi Aventis U.S. LLC, (Del. 2020).

Opinion

IN THE SUPREME COURT OF THE STATE OF DELAWARE

UNITED STATES OF AMERICA, STATE § OF CALIFORNIA, STATE OF § No. 256, 2019 COLORADO, STATE OF § CONNECTICUT, STATE OF § DELAWARE, DISTRICT OF COLUMBIA, § STATE OF FLORIDA, STATE OF § Certification of Questions of GEORGIA, STATE OF ILLINOIS, STATE § Law from the United States OF INDIANA, STATE OF IOWA, STATE § Court of Appeals for the Third OF LOUISIANA, COMMONWEALTH OF § Circuit MASSACHUSETTS, STATE OF § MICHIGAN, STATE OF MINNESOTA, § STATE OF MONTANA, STATE OF § NEVADA, STATE OF NEW JERSEY, § C.A. No. 18-2472 STATE OF NEW YORK, STATE OF § NORTH CAROLINA, STATE OF § OKLAHOMA, STATE OF RHODE § ISLAND, STATE OF TENNESSEE, § COMMONWEALTH OF VIRGINIA, § STATE OF WASHINGTON, STATE OF § WISCONSIN, ex rel. JKJ PARTNERSHIP § 2011 LLP, § § Relator Below, § Appellant, § § v. § § SANOFI-AVENTIS U.S. LLC, SANOFI- § AVENTIS U.S. SERVICES, INC., § AVENTIS, INC., AVENTIS § PHARMACEUTICALS, INC., BRISTOL- § MYERS SQUIBB COMPANY, BRISTOL- § MYERS SQUIBB PHARMACEUTICALS § HOLDING PARTNERSHIP, § § Defendants Below, § Appellees. § § § § Submitted: January 15, 2020 Decided: March 17, 2020

Before SEITZ, Chief Justice; VALIHURA, VAUGHN, TRAYNOR and MONTGOMERY-REEVES, Justices, constituting the Court en Banc.

Upon Certification of Questions of Law from the United States Court of Appeals for the Third Circuit. CERTIFIED QUESTIONS ANSWERED.

Jessica Zeldin, Esquire, Rosenthal, Monhait & Goddess, P.A., Wilmington, Delaware; Of Counsel: William H. Narwold, Esquire, Mathew P. Jasinski, Esquire (argued), Motley Rice LLC, Hartford, Connecticut; W. Scott Simmer, Esquire, Baron & Budd, P.C., Washington, District of Columbia for Appellants.

Kenneth J. Nachbar, Esquire (argued), Coleen W. Hill, Esquire, Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Delaware; Of Counsel: Anand Agneshwar, Esquire, Arnold & Porter Kaye Scholer LLP, New York, New York; John P. Elwood, Esquire, Kirk Ogrosky, Esquire, Daniel S. Pariser, Esquire, Murad Hussain, Esquire, Anna K. Thompson, Esquire, Arnold & Porter Kaye Scholer LLP, Washington, District of Columbia for Appellees.

VALIHURA, Justice: We are asked by the United States Court of Appeals for the Third Circuit to answer

three questions of law certified to us in accordance with Delaware Supreme Court Rule 41

(the “Questions”):

1. A limited liability partnership is formed to file and prosecute a specific lawsuit. Its formational documents say both that the partnership is not “a separate legal entity distinct from its Partners” under 6 Del. Code § 15- 201(a) and that the “withdrawal of a Partner shall not cause a dissolution of the Partnership.” If one of the partners leaves the partnership and a new partner joins, does it stay the same partnership? Or is it a new partnership?

2. If a “new” partnership was created upon the limited liability partnership’s change in membership, was the “old” partnership terminated immediately such that it was actually the “new” partnership that filed the second amended complaint? Or did the “old” partnership continue to exist long enough in the winding-up process to file the second amended complaint?

3. If the “old” limited liability partnership did not survive the membership change, may the original partners continue to prosecute the lawsuit as part of the “winding up” process?

The Questions arise in connection with the prosecution of a qui tam action under

the False Claims Act (“FCA”),1 In re: Plavix Marketing, Sales Practices and Products

Liability Litigation (No. II),2 brought against Sanofi-Aventis U.S. LLC, Sanofi-Aventis

U.S. Services, Inc., Aventis, Inc., Aventis Pharmaceuticals, Inc., Bristol-Myers Squibb

Company, and Bristol-Myers Squibb Pharmaceuticals Holding Partnership (together, the

“Defendants”). The relator bringing the action, on behalf of the United States and several

states, is JKJ Partnership 2011 LLP, a Delaware limited liability partnership. The

1 31 U.S.C. § 3729, et seq. 2 315 F. Supp. 3d 817 (D.N.J. 2018), appeal docketed, No. 19-2472 (3d Cir. July 3, 2018) [hereinafter Opinion].

3 partnership consists of three individuals who allegedly are each an “original source” of

knowledge upon which the allegations against Defendants are based.

The Questions arose when one of the partners was replaced by another partner, and

an amended complaint was filed shortly thereafter. Upon the filing of the amended

complaint, the Defendants moved to dismiss, alleging, in-part, that replacing the partner

was impermissible the under the FCA’s “first-to-file” bar. The United States District Court

for the District of New Jersey (the “District Court”) granted the motion on that ground.

The partnership appealed to the Third Circuit, which, in turn, certified the Questions that

relate to the “construction or application of” a Delaware statute “which has not been, but

should be, settled by” this Court.3

This is the opinion of the Court on the certified questions.

I. Factual and Procedural Background

A. The Qui Tam Litigation

Under our Rule 41, we rely only upon the undisputed facts. However, we provide

some background from the District Court’s May 30, 2018 Opinion (the “Opinion”),4 as

supplemented by the record before us, purely to provide context for the reader.

On October 26, 2011, two doctors and a Sanofi sales representative formed JKJ

2011 Partnership LLP (“JKJ”), a Delaware limited liability partnership. According to

3 App. to Opening Br. at A180 (3d Cir. Order of Certification). 4 Opinion, 315 F. Supp. 3d 817.

4 JKJ’s Partnership Agreement (the “Partnership Agreement”), JKJ was formed “to file and

prosecute” a whistleblower action against the Defendants.5

Section 1.03 of the Partnership Agreement states that “the Partnership shall not be

a separate legal entity distinct from its Partners.”6 The District Court explained the likely

reason for this provision:

Although the Third Circuit has not resolved the issue, the consensus of persuasive precedent suggests that, were JKJ a separate legal entity, the fact that it did not exist at the time the alleged fraud occurred would prevent it from being an “original source” with direct knowledge of the fraud under the pre-amendment FCA.7

On November 4, 2011, nine days after it was formed, JKJ filed the original qui tam

complaint (the “Complaint”) in the District Court, alleging that the Defendants failed to

disclose, as required by law, certain information regarding Plavix,® an antiplatelet drug

used to prevent heart attacks and strokes. The Complaint kept the partners’ identities

anonymous, identifying them as “Partner A,” “Partner B,” and “Partner C.” The

Partnership Agreement identified the partners as Jeffrey Stahl, Kelly Wood, and John

Venditto.8

On February 22, 2017, JKJ filed a second amended complaint (the “SAC”), further

developing its claim of Plavix’s® ineffectiveness for certain patients based on their genetic

makeup. JKJ alleges that Defendants made affirmative misrepresentations by

5 App. to Opening Br. at A110, A112 (Partnership Agreement). 6 Id. at A111. 7 Opinion, 315 F. Supp. 3d at 831. 8 App. to Opening Br. at A110.

5 “systematically and deliberately promot[ing] Plavix through false and misleading

advertising [and other marketing materials] that overstated [the drug’s] efficacy, and

minimized critical adverse event and risk information. Defendants would brand this their

‘Expand and Protect’ strategy.”9 JKJ alleges that Defendants created a logo used on Sales

Free access — add to your briefcase to read the full text and ask questions with AI

Related

William J. Troupe v. Milford J. Seby
416 F.2d 514 (Ninth Circuit, 1969)
Fairway Development Co. v. Title Insurance
621 F. Supp. 120 (N.D. Ohio, 1985)
Weeks v. McMillan
353 S.E.2d 289 (Court of Appeals of South Carolina, 1987)
Addy v. Short
89 A.2d 136 (Supreme Court of Delaware, 1952)
Lorillard Tobacco Co. v. American Legacy Foundation
903 A.2d 728 (Supreme Court of Delaware, 2006)
FI Du Pont, Glore Forgan & Company v. Silliman
310 A.2d 128 (Supreme Court of Delaware, 1973)
Kuhn Construction, Inc. v. Diamond State Port Corp.
990 A.2d 393 (Supreme Court of Delaware, 2010)
Helvering v. Smith
90 F.2d 590 (Second Circuit, 1937)
Paul v. Deloitte & Touche, LLP
974 A.2d 140 (Supreme Court of Delaware, 2009)
Gotham Partners, L.P. v. Hallwood Realty Partners, L.P.
817 A.2d 160 (Supreme Court of Delaware, 2002)
Elf Atochem North America, Inc. v. Jaffari
727 A.2d 286 (Supreme Court of Delaware, 1999)
Fike v. Ruger
754 A.2d 254 (Court of Chancery of Delaware, 1999)
Duncan v. Theratx, Inc.
775 A.2d 1019 (Supreme Court of Delaware, 2001)
Fike v. Ruger
752 A.2d 112 (Supreme Court of Delaware, 2000)
Evans v. Gunnip
135 A.2d 128 (Supreme Court of Delaware, 1957)
Gamble v. Penn Valley Crude Oil Corp.
104 A.2d 257 (Court of Chancery of Delaware, 1954)
Johnson v. Helicopter & Airplane Services Corp.
404 F. Supp. 726 (D. Maryland, 1975)
E.I. Du Pont De Nemours & Co. v. Shell Oil Co.
498 A.2d 1108 (Supreme Court of Delaware, 1985)
E.I. duPont De Nemours & Co. v. Florida Evergreen Foliage
744 A.2d 457 (Supreme Court of Delaware, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Sanofi Aventis U.S. LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-sanofi-aventis-us-llc-del-2020.